The invention relates to an animal feed additive comprising oligosaccharides, proteins, lipids, phenolic compounds and minerals, wherein the oligosaccharides comprise glucans, xylans, arabinans and mannans, and wherein degree of polymerisation (DP) of the oligosaccharides is DP1 to DP30 and to a method for preparing thereof from biomass.

The invention relates to an animal feed additive comprising oligosaccharides, proteins, lipids, phenolic compounds and minerals, wherein the oligosaccharides comprise glucans, xylans, arabinans and mannans, and wherein degree of polymerisation (DP) of the oligosaccharides is DP1 to DP30 and to a method for preparing thereof from biomass.

The invention relates to a process for the preparation of dry lyophilized powdered formulations of probiotic bacteria for monogastric animal (for example poultry birds) using a combination of different polymers through the process of encapsulation. The resulting lyophilized powders of probiotic bacteria are having increased viability during animal feed processing, storage and upon transfer to the monogastric animal's digestive system.

Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO.sub.3—), sulfuric acid group (—OSO.sub.3—), carboxylic group (—CO.sub.2—), phosphonic acid group (—OPO.sub.3.sup.2—), phosphate group (—OPO.sub.3.sup.2—), and sulfamic acid group (—NHSO.sub.3—). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO.sub.3—), sulfuric acid group (—OSO.sub.3—), carboxylic group (—CO.sub.2—), phosphonic acid group (—OPO.sub.3.sup.2—), phosphate group (—OPO.sub.3.sup.2—), and sulfamic acid group (—NHSO.sub.3—). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.

The invention relates to a dietary fiber rich composition derived from plants parts, preferably from ginger, turmeric and Emblica. The composition has at least 45% dietary fiber and most of it is insoluble fibre. The insoluble fibre mostly comprises of resistant starch, the composition has at least 15% resistant starch. The invention also relates to a method of extracting and enrichment of fibre from plant parts. The method further includes solvent extraction, acid treatment and enzymatic treatment. The Starch in the composition either enriched and/or chemical modified. The composition has a place in novel food products, for food processing purposes, as functional food, dietary supplementation purposes and pharmaceutical preparations. Composition has clinically significant activity towards fat loss, blood glucose regulation, inhibiting inflammation and enhance bioavailability.

The invention relates to a dietary fiber rich composition derived from plants parts, preferably from ginger, turmeric and Emblica. The composition has at least 45% dietary fiber and most of it is insoluble fibre. The insoluble fibre mostly comprises of resistant starch, the composition has at least 15% resistant starch. The invention also relates to a method of extracting and enrichment of fibre from plant parts. The method further includes solvent extraction, acid treatment and enzymatic treatment. The Starch in the composition either enriched and/or chemical modified. The composition has a place in novel food products, for food processing purposes, as functional food, dietary supplementation purposes and pharmaceutical preparations. Composition has clinically significant activity towards fat loss, blood glucose regulation, inhibiting inflammation and enhance bioavailability.

There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.